SOPHiA GENETICS Reports Strong Q4 2025 Results Amid Accelerated Adoption of AI-Powered Genomic Solutions

SOPHiA GENETICS S.A. delivered a standout performance in the fourth quarter of 2025, reporting total revenue of €74.3 million, a 17.2% year-over-year increase. This growth was fueled by a 22% rise in recurring subscription revenue, reflecting strong customer retention and expanded use of its SOPHiA DDM platform in hospitals and research institutions worldwide. The company also achieved a non-GAAP net loss of €5.4 million, marking a 31% improvement compared to the same period in 2024, signaling progress toward operational efficiency. The expansion of SOPHiA’s footprint in the U.S. market contributed significantly to results, with North American revenue rising 28% year-over-year. Key installations in major academic medical centers and oncology networks highlighted the platform’s integration into routine diagnostic workflows. Additionally, the company secured six new international partnerships in Europe and Asia-Pacific, reinforcing its position as a leader in AI-powered genomic data interpretation. SOPHiA’s strategic focus on precision medicine has resonated with healthcare providers seeking scalable solutions for complex genetic data analysis. The company’s platform processed over 850,000 genomic cases in 2025, a 40% increase from the prior year, underscoring heightened demand. Gross margin improved to 78.6%, up from 75.2% in Q4 2024, driven by software optimization and higher-margin service delivery. The results have drawn attention from investors, with SOPH shares gaining 14% in after-hours trading. The performance also influenced broader healthcare technology indices, contributing to gains in XLV and IHI. Analysts note that SOPHiA’s trajectory reflects a broader shift toward AI-integrated diagnostics and the increasing commercial viability of genomic data platforms in clinical practice.